Safe dose reduction of XXXX pre-medication for @entity1205 in @entity135 treatment.

@entity1 @entity135 @entity1910 @entity4 @entity619 @entity56 @entity5143 @entity551 @entity1205 @entity479
CONCLUSION: The results suggest that the rate of severe @entity56 did not increase when the @entity619 pre-medication dose was reduced to 11   mg prior to @entity1205 infusion. OBJECTIVES: @entity619 is commonly used to prevent the adverse effects of @entity1205 in @entity135 treatment. The recommended @entity619 dose is 8   mg orally twice daily for 3 days for each injection of @entity1205 . This pre-medication reduces the incidence of adverse effects to 1-2% of treated @entity1 . However, many adverse events have been observed with long-term @entity479 use. In an attempt to balance the benefits and harms of @entity479 prophylaxis without affecting the safety of @entity1205 , this study tried to reduce the duration and dose of @entity619 . METHODS: In this study, a total of 336 @entity1 underwent @entity1205 -containing protocols (TP or TPF regimens) to treat @entity135 . @entity1205 was given in doses of 70   mg/m(2) once every 3 weeks. @entity619 (0.75   mg/tablet) pre-medication was given in different doses (45, 24, 18, and 11   mg); the minimum dose included 6   mg orally in the morning and 5   mg intravenously immediately before @entity1205 infusion. RESULTS: Severe @entity56 were experienced by none of 30 @entity1 who received 45   mg (7.5   mg orally twice for 3 days) @entity619 pre-medication in 125 cycles, none of 20 @entity1 who received 24   mg (6   mg orally twice for 2 days) @entity619 in 77 cycles, and none of 20 @entity1 who received 18   mg (4.5   mg orally twice for 2 days) @entity619 in 79 cycles. Three of 266 @entity1 who received 11   mg @entity619 in 1054 applications developed a severe @entity56 with @entity5143 and @entity551 , two of the 266 @entity1 developed a severe @entity1910 , and four developed severe @entity4 .
